FDA Approves World’s First Dual Glucose-Ketone Continuous Monitoring Wearable for Diabetes Patients: Early DKA Risk Detection Enabled

August 30, 2026

GIGAZINE Japan

Overview

GIGAZINE reports that the U.S. FDA has approved the world’s first wearable device for continuous dual glucose and ketone monitoring in diabetes patients. This is Abbott’s Libre Duo 10 Day, providing real-time data via a patch sensor to enable early detection of diabetic ketoacidosis (DKA) risk and support patient health management. This approval marks a groundbreaking advance in DKA prevention without interfering with daily activities.

In Depth

Key Findings

On August 26, 2026, Japanese technology news site GIGAZINE reported that the U.S. Food and Drug Administration (FDA) has authorized the world’s first wearable device capable of continuously monitoring both blood glucose and ketone levels for individuals with diabetes. The approved device is Abbott’s Libre Duo 10 Day system, which provides real-time data via a patch sensor, enabling early detection of diabetic ketoacidosis (DKA) risk and supporting safer patient health management. This represents a groundbreaking step in addressing the long-standing challenge of DKA prevention in diabetes management, offering a convenient and continuous approach.

Technical and Clinical Details

The Libre Duo 10 Day is a compact, thin patch-type sensor that integrates ketone (β-hydroxybutyrate) measurement functionality with traditional continuous glucose monitoring (CGM) technology. Patients wear this device on their arm, continuously acquiring blood glucose and ketone level data for up to 10 days. GIGAZINE highlights the device’s unobtrusive design, predicting that its user-friendly nature will contribute to its widespread adoption. Through real-time data and trend analysis, it becomes possible for patients, particularly those with Type 1 diabetes or insulin-dependent patients, to promptly detect rising ketone levels, for instance during illness (sick days), which could lead to DKA. This capability is expected to significantly reduce the risk of emergency hospital visits and hospitalizations due to DKA.

Background and Industry Context

Diabetic ketoacidosis (DKA) is a severe complication where insufficient insulin leads to the breakdown of body fat and excessive production of ketones, causing the blood to become acidic. DKA can progress rapidly, leading to impaired consciousness or coma, and can be life-threatening. Previous methods for ketone measurement required blood or urine tests, which provided only a snapshot of the condition at a specific time. GIGAZINE points out that the Libre Duo 10 Day solves these traditional challenges, becoming a powerful tool for diabetes patients to live with greater peace of mind. The convergence of wearable devices and medical technology is part of a global trend accelerating the enhancement of preventive medicine and a shift towards patient-centric care.

Strategic Significance and Outlook

This FDA authorization marks a significant milestone in the evolution of diabetes management technology. GIGAZINE suggests that Abbott’s innovation could encourage other medical device manufacturers to develop similar integrated biosensors, thereby elevating the overall technological standard of the market. In the future, such multifunctional wearable devices are likely to be applied to monitoring other chronic diseases, contributing to the realization of ‘personalized healthcare,’ where an individual’s health status can be comprehensively understood. Investors should pay close attention to the competition and growth opportunities in this emerging market segment.

Source: https://gigazine.net/gsc_news/en/20260826-fda-authorizes-wearable-monitor-ketone-glucose/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.